Skip to main content
Skip to main content
Back to Grand Rounds
Grand RoundsWeekly Evidence Brief

Plastic Surgery

Edition

30-Second Takeaway

  • Reduced-dose preoperative radiotherapy (**36 Gy**) achieved excellent 5-year local control in myxoid liposarcoma.
  • Root-coverage surgery for multiple gingival recessions yields substantial average root coverage and high patient esthetic satisfaction.

Week ending May 16, 2026

Grand Rounds: Recent practical evidence across AI, reconstruction, radiotherapy, and survivorship tools

EHR-integrated AI risk scores did not increase patient conversations about graft-loss options

NPJ DIGITAL MEDICINEMay 15, 2026

In a single-center randomized trial of 76 kidney transplant recipients, passive EHR display of a machine-learning 1-year graft-loss risk did not change patient-reported conversations (39% vs 40%, p=1.00). Secondary outcomes including shared decision-making metrics, clinician–patient relationship measures, and distress showed no significant differences. User feedback noted low and variable tool uptake and workflow barriers as likely reasons for null effects. Implication: passive availability of risk estimates alone is insufficient; interventions must actively integrate into workflows and explicitly support SDM.

Surgical root coverage improves professional and patient esthetic outcomes for multiple recessions

PERIODONTOLOGY 2000May 14, 2026

Meta-analysis of 32 RCTs (1012 patients, 3589 recessions) found mean Root Coverage Esthetic Score 8.31 and patient VAS satisfaction 8.59. Mean root coverage averaged 82.6% and complete root coverage pooled at 62.7% across techniques. Postoperative pain was low (VAS mean 2.67), and gains in attachment and keratinized tissue were consistent. Applicability: CAF and tunnel approaches with connective tissue grafts or substitutes reliably improve esthetics; counsel patients about likelihood of complete coverage.

Reduced preoperative radiotherapy (36 Gy) gave excellent 5-year local control in myxoid liposarcoma

JAMA ONCOLOGYMay 16, 2026

The phase 2 DOREMY trial (n=90, median follow-up 66 months) reported 5-year local recurrence-free survival 97.4%. Five-year progression-free, disease-specific, and overall survival were 81.0%, 89.5%, and 88.5%, respectively. Wound complications occurred in 21% (16% required intervention), and late grade 2–3 toxic effects were uncommon. Caveat: single-group, nonrandomized design—discuss risks and alternatives with patients in multidisciplinary teams.

References

Numbered in order of appearance. Click any reference to view details.

Additional Reads

Optional additional studies from this edition.

Edition context

Clinical signal

  • Be cautious integrating passive EHR AI tools without workflow redesign and direct SDM support.
  • Consider 36 Gy preoperative radiotherapy for localized myxoid liposarcoma after multidisciplinary discussion.
  • Expect good esthetic outcomes from CAF or tunnel techniques combined with grafts; discuss realistic complete coverage rates (~**63%**).